UpcomingPDUFA target action date

Arikayce (amikacin liposome inhalation suspension)

Insmed (INSM)

Marketer take

The company says it would launch under an expanded MAC lung disease label, which would widen the pulmonologist and ID audience beyond the current refractory-patient label.

Sponsor company
Insmed (INSM)
Indication
Expanded label in MAC lung disease (sNDA, priority review)
Therapeutic area
Pulmonology, Infectious disease
Event
PDUFA target action date
Date
Jan 28, 2027
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move